TGFB1 and cancer: It thus follows that, given the important and non-redundant functions of each TGF-β isoform, isoform-selective antagonists, particularly against TGF-β1, are more likely to be effective and safer cancer therapeutic tools than pan TGF-β inhibitors, particularly in the context of immunotherapy.